BIOXYTRAN, INC
For the period ended Mar 2, 2026. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 2, 2026 · Filed Mar 2, 2026
Use the contents to explore the available documents and sections.
BIXTStored price and day change unavailable
Contents
EX-99.1 · Study Design
Study Design
The Phase 1b/2a study enrolled 39 participants in India with RT-PCR-confirmed SARS-CoV-2 infection and mild to moderate disease. Participants were randomized to receive one of three dose levels of ProLectin-M plus standard of care (SOC), or placebo plus SOC, administered over five days.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.